<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25212" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>MMR Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bailey</surname>
            <given-names>Adrian</given-names>
          </name>
          <aff>University of Ottawa</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapra</surname>
            <given-names>Amit</given-names>
          </name>
          <aff>Southern Illinois University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adrian Bailey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Sapra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25212.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Measles-containing vaccines are approved by the US Food and Drug Administration (FDA) and indicated for the routine immunization of children and adolescents. These vaccines are also recommended for adults born after 1970 who have not been immunized. Adults born before 1970 are generally considered to have acquired natural immunity to measles. However,&#x000a0;susceptible patients, such as healthcare workers, military personnel, and travelers outside North America, should receive the measles-mumps-rubella (MMR) vaccine to safeguard against potential infection.</p>
        <p>The MMR vaccine is a live attenuated combination vaccine&#x000a0;formulated with live attenuated viruses, making it a harmless, less-virulent version of the infectious agents it targets. This vaccine is designed to prevent&#x000a0;infectious diseases such as measles, mumps, and rubella by strengthening the immune system. Due to its live attenuated nature, the MMR vaccine demonstrates&#x000a0;high efficacy but necessitates multiple doses for complete&#x000a0;immunity to be attained. Furthermore,&#x000a0;this vaccine is recommended for specific patient populations as post-exposure prophylaxis. This activity provides an overview of the MMR vaccine's indications, mechanism of action, administration, and notable adverse reactions for the interprofessional healthcare team members for safely administering the vaccine to patients, depending on various patient populations and clinical settings. This activity&#x000a0;aims to provide healthcare professionals with the essential knowledge of vaccine administration, thereby enhancing patient outcomes by promoting acceptance of the MMR vaccine and preventing associated infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients eligible for MMR vaccination based on age, immunization history, and risk factors.</p></list-item><list-item><p>Implement evidence-based guidelines for administering the MMR vaccine, considering factors such as timing, dosing, administration schedules, and individual patient needs.</p></list-item><list-item><p>Select alternative vaccination strategies for patients with specific contraindications or medical conditions that preclude MMR vaccine use.</p></list-item><list-item><p>Collaborate with other healthcare professionals to communicate effectively with patients and caregivers&#x000a0;about the benefits, risks, and importance of MMR vaccination to&#x000a0;optimize patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25212&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25212">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25212.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Measles-containing vaccines are approved by the US Food and Drug Administration (FDA) and indicated for the routine immunization of children and adolescents. These vaccines are also recommended for adults born after 1970 who have not been immunized. Adults born before 1970 are generally considered to have acquired natural immunity to measles. However,&#x000a0;susceptible patients, such as healthcare workers, military personnel, and travelers outside North America, should receive the measles-mumps-rubella (MMR) vaccine to safeguard against potential infection.<xref ref-type="bibr" rid="article-25212.r1">[1]</xref></p>
        <p>The MMR vaccine is a live attenuated combination vaccine&#x000a0;formulated with live attenuated viruses, making it a harmless, less-virulent version of the infectious agents it targets. This vaccine is designed to prevent&#x000a0;infectious diseases such as measles, mumps, and rubella by strengthening the immune system. Due to its live attenuated nature, the MMR vaccine demonstrates&#x000a0;high efficacy but necessitates multiple doses for complete&#x000a0;immunity to be attained. Furthermore,&#x000a0;this vaccine is recommended for specific patient populations as post-exposure prophylaxis.</p>
        <p>Vaccinating women before or during reproductive years is also important, as rubella can cause congenital malformations in the fetus. Recommendations&#x000a0;for non-immunized female patients who wish to become pregnant&#x000a0;include&#x000a0;vaccination with the MMR vaccine no less than&#x000a0;1 month before&#x000a0;conception. If the patient is pregnant, the MMR vaccine is contraindicated, as it is a live attenuated vaccine, and therefore, a theoretical risk is posed to the fetus. However, for women&#x000a0;who receive the MMR vaccine during pregnancy, pregnancy should&#x000a0;not be terminated based on teratogenic risk; no evidence demonstrates a significant teratogenic risk from the MMR or measles-mumps-rubella-varicella (MMRV) vaccine.<xref ref-type="bibr" rid="article-25212.r2">[2]</xref><xref ref-type="bibr" rid="article-25212.r3">[3]</xref>&#x000a0;</p>
        <p>In measles or rubella outbreaks, pregnant women may be given the MMR vaccine as the potential benefits of vaccination outweigh the risks. The MMR vaccine should&#x000a0;be administered after delivery to non-immunized patients, as the MMR vaccine is safe during breastfeeding.<xref ref-type="bibr" rid="article-25212.r4">[4]</xref>&#x000a0;</p>
        <p>The administration of the MMR vaccine is appropriate for specific patient populations as post-exposure prophylaxis. Patient populations given the MMR vaccine as post-exposure prophylaxis include&#x000a0;infants aged between 6 and 12 months who are immunocompetent and have been exposed in the last 72 hours and non-pregnant patients 12 months or older who are immunocompetent with exposure in the previous&#x000a0;6 days.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref></p>
        <p>Individuals less than 6 months of age, those aged between 6 and 12 months who have been exposed to measles, mumps, or rubella more than 72 hours prior, as well as pregnant individuals or those who are immunocompromised, should receive an immunoglobulin preparation for post-exposure prophylaxis.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref><bold>&#x000a0;</bold>In&#x000a0;June 2022, the FDA&#x000a0;approved a&#x000a0;new MMR vaccine&#x000a0;for individuals aged 12 months or older, which is interchangeable with the existing MMR vaccine.<xref ref-type="bibr" rid="article-25212.r6">[6]</xref></p>
      </sec>
      <sec id="article-25212.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The MMR vaccine is a live attenuated combination vaccine&#x000a0;formulated with live attenuated viruses, making it a harmless, less-virulent version of the infectious agents from which it provides protection. The MMR vaccine stimulates the immune system to protect against measles, mumps, and rubella. Due to its live attenuated nature, the MMR vaccine demonstrates&#x000a0;high efficacy but necessitates multiple doses for complete&#x000a0;immunity to be attained.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref>&#x000a0;Furthermore,&#x000a0;this vaccine is recommended for specific patient populations as post-exposure prophylaxis.</p>
        <p>The&#x000a0;3 live attenuated viruses in the new MMR vaccine&#x000a0;are genetically similar to the corresponding components of the existing MMR vaccine.&#x000a0;Humoral immunity&#x000a0;is evaluated&#x000a0;from the clinical data&#x000a0;of 13 randomized controlled trials, and the serologic response thresholds were&#x000a0;achieved for all antigens. The Advisory Committee on Immunization Practices (ACIP) has determined the newly approved MMR vaccine to be immunogenic and safe.<xref ref-type="bibr" rid="article-25212.r6">[6]</xref></p>
      </sec>
      <sec id="article-25212.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Estimates of the effectiveness of the MMR vaccine are 99% in measles prevention after&#x000a0;a second vaccination, over 95% in the prevention of mumps, and 90% in the prevention of rubella after a single dose. ACIP&#x000a0;suggests that vaccine doses in a series should&#x000a0;arrive from the same manufacturer; however, vaccination should not be&#x000a0;delayed if the vaccine from the same manufacturer is unavailable. Clinical trials have&#x000a0;demonstrated that the new MMR vaccine is safe and&#x000a0;efficacious when administered as a second dose.<xref ref-type="bibr" rid="article-25212.r7">[7]</xref><xref ref-type="bibr" rid="article-25212.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The first dose should be administered to individuals aged&#x000a0;12 to 15 months, and the second dose should be administered between ages 4 and 6. The second dose is preferably administered before kindergarten or school entry. Note that the interval between doses should not be shorter than 28 days.<xref ref-type="bibr" rid="article-25212.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The vaccine can be given in 2 doses to individuals aged 12 months to 13 years for unimmunized children and adolescents.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For unimmunized adults born after 1970,&#x000a0;1 dose should be given unless they are traveling outside North America, working in health care, students in post-secondary educational settings, or military personnel.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For unimmunized adults born before 1970, 1 dose should be given if they are students in post-secondary educational settings or traveling outside North America and&#x000a0;2 doses if they work in health care or are military personnel.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The recommendation is to give the first and/or second dose of MMR in advance to children who live or travel in areas with an outbreak of measles (defined as at least 3 cases with a temporal and spatial relationship) and children traveling outside US borders.&#x000a0;In the specified situations, the initial dose of MMR should be administered between 6 and 11 months of age, followed by subsequent vaccinations according to the recommended schedule&#x02014;2 doses of vaccine, with an interval of at least 28 days apart, typically administered between 12 and 15 months of age.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In the case of measles outbreaks, a vaccine can be given to infants aged 6 months. Then vaccinations can be continued according to a generally accepted schedule (2 doses in 13 to 14 months and&#x000a0;10 years, respectively).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Children aged between 12 and 23 months should receive the MMR vaccine and a univalent varicella vaccine at the same visit instead of the MMRV vaccine to reduce the risk of fever and febrile seizures. The risk is estimated to be around&#x000a0;1 additional febrile seizure per 2300 to 2800 doses of MMRV vaccine in this patient cohort.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with laboratory confirmation of measles, mumps, or rubella immunity are considered immune to this disease,&#x000a0;and no need for immunization vaccination exists. In practice, however,&#x000a0;2 doses of the MMR vaccine are also given in this situation, which is dictated by the lack of availability of monovalent vaccines against these viruses.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref>&#x000a0;Seronegative patients who have proof of adequate immunization do not require further vaccination.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No dose adjustment is provided in the vaccine labeling. Expert opinion&#x000a0;is&#x000a0;that MMR vaccines should be administered early&#x000a0;in chronic liver disease for&#x000a0;effective immune response. The American Society of Transplantation&#x000a0;Infectious Diseases Community of Practice suggests that children should be vaccinated before liver transplantation.<xref ref-type="bibr" rid="article-25212.r9">[9]</xref></p>
        <p><bold>Renal impairment: </bold>No dose adjustment is provided.</p>
        <p><bold>Pregnancy considerations: </bold>Pregnant women who have not been vaccinated and have laboratory-confirmed measles disease should receive intravenous (IV) immunoglobulin after exposure. Measles in pregnant women may have a more severe course and serious complications.<xref ref-type="bibr" rid="article-25212.r3">[3]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The CDC states that the MMR vaccine administered to mothers during lactation does not affect the safety of infants or mothers. The rubella vaccine virus&#x000a0;can&#x000a0;be secreted in breast milk. The rubella virus is attenuated and generally does not infect the infant. However, transmission and mild clinical infection are possible. No definitive evidence suggests the presence of live attenuated mumps or measles vaccine virus in the breast milk. Additionally, the absence of exclusive breastfeeding until&#x000a0;5 months of age can result in poor response to measles vaccination.<xref ref-type="bibr" rid="article-25212.r4">[4]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The&#x000a0;efficacy and&#x000a0;safety of the MMR vaccine in infants 12 months or younger are inconclusive. ACIP recommends&#x000a0;2 doses of MMR vaccine administered&#x000a0;&#x02265;28 days apart for catch-up immunization of previously unvaccinated children.<xref ref-type="bibr" rid="article-25212.r6">[6]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>Clinical studies of&#x000a0;MMR vaccines&#x000a0;have not evaluated&#x000a0;patients aged&#x000a0;65 or younger if they respond differently from younger&#x000a0;individuals.</p>
        <p>
<bold>Post-Exposure Prophylaxis</bold>
</p>
        <p>Immunoglobulin (400 mg/kg) can be administered&#x000a0;6 days after exposure. The intent is to prevent or reduce the severity of measles, but it is not given to immunocompetent persons who have received&#x000a0;1 dose of MMR after 12 months of age. This post-exposure prophylaxis is only for patients exposed to measles who have an increased risk of complications and are contraindicated to MMR vaccination. This group includes patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe immunodeficiency, regardless of immune status or immunization</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>After a bone marrow transplant, up to at least 12 months after the end of immunosuppressive therapy or longer if there is a graft-versus-host reaction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treated for acute lymphoblastic leukemia until at least&#x000a0;6 months after&#x000a0;completing immunosuppressive chemotherapy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infected with HIV and a percentage of CD4 cells less than 15% (all age groups) or CD4 cell counts below 200 cells/mm<sup>3</sup> (aged 5 and older). They have not received the MMR vaccine after effective antiretroviral therapy.</p>
          </list-item>
        </list>
        <p>Newborn babies and infants aged up to 6 months should receive immunoglobulin intramuscularly (IGIM) at a dose of 0.5 mL/kg (maximum dose 15 mL) or intravenous immunoglobulin (IVIG) 400 mg/kg within&#x000a0;6 days of exposure.</p>
        <p>Infants aged 6 to 12 months may receive the MMR vaccine within 72 hours of exposure or IGIM at 0.5 mL/kg (maximum dose of 15 mL) or IVIG 400 mg/kg within&#x000a0;6 days of exposure.</p>
        <p>For children aged at least 12 months, the MMR vaccination is&#x000a0;preferred to IGIM or IVIG.</p>
        <p>After exposure, children with contraindications for MMR vaccination should receive IVIG 400 mg/kg instead of IGIM.<xref ref-type="bibr" rid="article-25212.r1">[1]</xref></p>
      </sec>
      <sec id="article-25212.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects associated with vaccines are listed below.</p>
        <p>
<bold>MMR Vaccine</bold>
</p>
        <p>Adverse events tend to occur with the first dose.&#x000a0;1 to 3 weeks following vaccination, 5% of immunized children experience malaise and fever, which can present with or without a rash that lasts up to 3 days.<xref ref-type="bibr" rid="article-25212.r2">[2]</xref></p>
        <p>
<bold>MMRV Vaccine</bold>
</p>
        <p>Ten percent&#x000a0;or more of vaccine recipients experience redness and pain at the injection site or a fever of 39 &#x000b0;C or less. Less than 1% to 10% of patients experience a measles-like, rubella-like, or varicella-like rash in addition to swelling and a fever greater than 39 &#x000b0;C.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref><xref ref-type="bibr" rid="article-25212.r10">[10]</xref></p>
        <p>
<bold>Rubella-Containing Vaccines</bold>
</p>
        <p>Patients receiving rubella-containing vaccines may experience acute transient arthritis or arthralgia 1 to 3 weeks after immunization. These symptoms last 1 to 3 weeks and rarely recur. These symptoms are more common in post-pubertal females, who develop arthralgia in 25% of cases and arthritis in 10% of patients after immunization.&#x000a0;No evidence of an increased risk of new-onset chronic arthropathies exists.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref></p>
        <p>
<bold>Immune Thrombocytopenic Purpura</bold>
</p>
        <p>A rare adverse reaction to the MMR or MMRV vaccine is immune thrombocytopenic purpura, which may occur within&#x000a0;6 weeks of immunization. In most children, immune thrombocytopenic purpura resolves within&#x000a0;3 months without complication. In these cases, serologic status can undergo an evaluation to determine the need for an additional dose. Clinicians should consider the risks of another adverse event of immune thrombocytopenic purpura before a second dose of the vaccine is required.<xref ref-type="bibr" rid="article-25212.r11">[11]</xref></p>
        <p>
<bold>Encephalitis</bold>
</p>
        <p>Encephalitis occurs in approximately 1 per million doses, compared to 1 in 1000 with infection with the measles virus.&#x000a0;Measles encephalitis is due to disseminated measles vaccine virus infection. The neuropathological&#x000a0;examination reveals inclusion-body encephalitis.<xref ref-type="bibr" rid="article-25212.r12">[12]</xref></p>
        <p>
<bold>Febrile Seizures</bold>
</p>
        <p>Children between the ages of 12 and 23 months should receive the MMR vaccine and a univalent varicella vaccine at the same visit instead of an MMRV vaccine to reduce the risk of fever and febrile seizures. The incidence of febrile&#x000a0;seizures is highest after the&#x000a0;first MMR dose.<xref ref-type="bibr" rid="article-25212.r13">[13]</xref>&#x000a0;The risk is estimated to be around&#x000a0;1 additional febrile seizure per 2300&#x000a0;to 2800 doses of MMRV vaccine in this patient cohort.<xref ref-type="bibr" rid="article-25212.r14">[14]</xref><xref ref-type="bibr" rid="article-25212.r15">[15]</xref></p>
        <p>
<bold>Allergies</bold>
</p>
        <p>The trace amount of egg or chicken protein in the MMR and MMRV vaccine is&#x000a0;insufficient to cause an allergic reaction in those who are egg-allergic. Recently&#x000a0;approved MMR vaccine does not contain gelatin.<xref ref-type="bibr" rid="article-25212.r16">[16]</xref></p>
      </sec>
      <sec id="article-25212.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Booster doses with a measles-containing vaccine after appropriate vaccination is not necessary.</p>
        <p>
<bold>Contraindications of Vaccines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe allergic reaction/anaphylaxis after a previous dose of MMR/MMRV or after one of the components of the vaccine, such as neomycin and gelatin.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy or planning should be discouraged within 28 days of vaccination due to the risk of congenital rubella. However, performing a pre-vaccination pregnancy test is unnecessary if the patient denies pregnancy.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immunodeficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hematopoietic proliferative diseases</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Solid tumors or chemotherapy&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Congenital&#x000a0;immunodeficiency&#x000a0;disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Long-term immunosuppressive treatment, when administering high doses of steroids, which is at least 2 mg/kg/d or at least 20 mg/d prednisone equivalents for persons over 10 kg for more than 14 consecutive days, MMR vaccination should be postponed a month. However, lower systemic corticosteroids, supporting physiological doses (the so-called replacement therapy), and local corticosteroid injections (eg, into joints or tendons) are not contraindications to MMR vaccination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>HIV infection and severe immunosuppression is defined as the percentage of CD4+ lymphocytes (CD4) less than 15% at any age. In case the percentage of CD4 is not available, the threshold values are as follows: CD4 less than 750/mL for children aged 12 months; CD4 below 500/mL for children aged 1&#x000a0;to 5; CD4 less than 200/mL for children&#x000a0;aged 5 and older.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Family history for congenital or hereditary immunodeficiency in parents or siblings, except for persons whose immunological system&#x000a0;is confirmed by laboratory tests.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment in the last 11 months with blood products or immunoglobulins may contain antibodies or inhibit the host response to a live vaccine. Therefore, the recommended interval&#x000a0;for&#x000a0;such treatment to MMR vaccination is from 3 to 11 months, depending on the type of&#x000a0;transfused preparation.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anamnesis with thrombocytopenia or thrombocytopenia may show an increased risk of clinically significant thrombocytopenia after immunization with MMR or MMRV. Therefore, decisions on the first dose of MMR for children with a thrombocytopenia history must consider the risks and benefits. In general, the benefits outweigh the risks. Factors to be evaluated when making this decision include:
<list list-type="bullet"><list-item><p>Relapse of thrombocytopenia after MMR in patients with a history of thrombocytopenia (related and unrelated to the vaccine).</p></list-item><list-item><p>Probability of the child's exposure to measles, mumps, and rubella (eg, planned trips abroad, the epidemiology in the place of residence or stay of the child).</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Before the second dose of MMR vaccination, clinicians can perform serological tests to determine the necessity. Children with a protective level of measles, mumps, and rubella antibodies do not need a second dose. However, for children with a history of thrombocytopenia who do not have a protective level of measles, mumps, or rubella antibodies, decisions on administering a second dose of MMR are&#x000a0;assessed&#x000a0;individually&#x000a0;for the risks and benefits.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute moderate or severe disease, with or without fever, to avoid the imposition of any vaccine reaction, symptoms of infection, and the vaccine burden with symptoms due to infection. Vaccinate children with mild infections (eg, upper respiratory tract infection, ear infection, diarrhea). Postponing vaccination in such a situation unnecessarily delays the implementation of the immunization program and lengthens the susceptibility to infection.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Contraindications Do Not Constitute</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A positive tuberculin test in people with active TB infection before vaccination. A simultaneous tuberculin test should be performed either on the day of MMR vaccination or 4&#x000a0;to 6 weeks after because the measles virus in the vaccine may weaken the skin reaction to tuberculin.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Breastfeeding period</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy of the mother of a child who is to receive a vaccine or pregnancy in a person near the child</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reproductive period</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A person who is&#x000a0;immunocompromised in the family or immediate environment</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic HIV infection or HIV infection with mild symptoms, without immune disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Allergy to egg protein in children with a history of mild allergy to a hen egg, the risk of anaphylactic reaction after MMR vaccination is the same as in the general population.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In children with severe allergies - anaphylaxis or an immediate reaction after ingestion. Allergy to egg protein is&#x000a0;automatically included in the group at higher risk of sudden allergic reactions after vaccines. In the case of MMR, gelatin and neomycin are more allergenic to egg protein.<xref ref-type="bibr" rid="article-25212.r14">[14]</xref><xref ref-type="bibr" rid="article-25212.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25212.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor for seizures and anaphylaxis following administration.<xref ref-type="bibr" rid="article-25212.r17">[17]</xref></p>
      </sec>
      <sec id="article-25212.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Limited data are available regarding the safety of administering an additional dose of the MMR vaccine. The administration of an additional dose of a vaccine may be necessary in cases where there is uncertainty about a person's vaccination history or due to programmatic errors, such as vaccination mistakes. Among 5067 reported instances of excess vaccine doses administered between 2007 and 2017, three-fourths of cases did not result in adverse events following immunization (AEFI). The most commonly reported adverse health events were pyrexia (12.8%), injection site erythema (9.7%), injection site pain (8.9%), and headache (6.6%). The percentage of adverse health events among these cases was comparable to all cases submitted to the Vaccine Adverse Event Reporting System (VAERS) during the same study period.<xref ref-type="bibr" rid="article-25212.r18">[18]</xref></p>
      </sec>
      <sec id="article-25212.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Vaccination with the MMR vaccine requires an interprofessional approach as the proper administration of the vaccine changes according to the patient population and the clinical scenario.&#x000a0;The mumps outbreaks have increased&#x000a0;in the US since 2006. Due to the resurgence of mumps and the risk associated with rubella and measles, increasing&#x000a0;MMR coverage is necessary.&#x000a0;The availability of MMR vaccines from&#x000a0;different manufacturers&#x000a0;ensures&#x000a0;the continuous supply of vaccines.<xref ref-type="bibr" rid="article-25212.r6">[6]</xref><xref ref-type="bibr" rid="article-25212.r19">[19]</xref></p>
        <p>Vaccination of children with neurological diseases should follow accepted rules and vaccination schedules. One should remember that the risk of severe infection, the need for hospitalization, and complications in children with chronic disease are significantly higher than in the healthy population. Also, each infection causes a break in rehabilitation, adversely affecting the child's neurological status. Also, children with chronic diseases are more likely to be in healthcare facilities,&#x000a0;increasing&#x000a0;infection risk.</p>
        <p>Contraindications to MMR vaccination in children with neurological diseases are limited and temporary.<xref ref-type="bibr" rid="article-25212.r5">[5]</xref> They include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Undetermined neurological diagnosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Suspicion of progressive central nervous system disease with epilepsy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Six months after the last convulsion seizure</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Unstabilized neurological condition</p>
          </list-item>
        </list>
        <p>Contraindications to MMR vaccination do not constitute:</p>
        <list list-type="bullet">
          <list-item>
            <p>Epilepsy with an excellent response to treatment (at least&#x000a0;6 months without seizures)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A neurological disorder before the start of vaccination</p>
          </list-item>
        </list>
        <p>In children with epilepsy, the recommendation is to administer antipyretic drugs for 6&#x000a0;to 12 days after administration of MMR - fever that may occur as an adverse reaction may trigger seizures.<xref ref-type="bibr" rid="article-25212.r2">[2]</xref><xref ref-type="bibr" rid="article-25212.r3">[3]</xref></p>
        <p>Another recommendation is to educate patients with a multi-disciplinary team about vaccination's perceived but false risks. For example, the association of MMR with autism spectrum disorder (ASD) has aroused much controversy in recent years. Several antivaccine advocacy groups put the hypothesis linking autism and inflammatory bowel disease with MMR vaccination forward in the last century.<xref ref-type="bibr" rid="article-25212.r20">[20]</xref></p>
        <p>In 1998, Lancet published an article&#x000a0;where researchers reported a link between the MMR vaccine and intestinal leukemia.&#x000a0;The article's basis was the temporal relationship between the increase in ASD diagnoses (observed since the 1980s) and the rise in recommended childhood vaccines - against haemophilus influenzae type B, hepatitis B, chickenpox, pneumococci, influenza, and&#x000a0;MMR vaccine.<xref ref-type="bibr" rid="article-25212.r20">[20]</xref><xref ref-type="bibr" rid="article-25212.r21">[21]</xref></p>
        <p>The thesis put forward by Wakefield's team&#x000a0;is the starting point for many epidemiological and prospective studies worldwide that have ruled out a cause-and-effect relationship between vaccination (including MMR) and the occurrence of ASD or inflammatory bowel disease. Subsequent analysis proved that increased ASD diagnoses resulted from changes in ASD recognition criteria as a neurodevelopmental disorder and increasing awareness of this problem.</p>
        <p>Prospective studies have shown that ASD symptoms often occur in the first year of life, before the first dose of MMR. In 2004, the journalist revealed that Wakefield's test was conducted in a manner that did not follow medical ethics and was inaccurate. Most of the study's authors officially withdrew unreliable applications, and the Lancet completely retracted the article in 2010.<xref ref-type="bibr" rid="article-25212.r22">[22]</xref>&#x000a0;However, if adverse events occur following immunization (AEFI), clinicians should report them through the VAERS.<xref ref-type="bibr" rid="article-25212.r23">[23]</xref></p>
        <p>Interprofessional coordination and collaboration&#x000a0;among clinicians, specialists, pharmacists, nurses, and public health professionals&#x000a0;can enhance patient outcomes when helping patients accept the MMR vaccine and prevent associated infections.&#x000a0;</p>
      </sec>
      <sec id="article-25212.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25212&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25212">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25212/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25212">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25212.s11">
        <title>References</title>
        <ref id="article-25212.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Temte</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Snider</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Seward</surname>
                <given-names>JF</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2010</year>
            <month>May</month>
            <day>07</day>
            <volume>59</volume>
            <issue>RR-3</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">20448530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLean</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Fiebelkorn</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Temte</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>GS</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2013</year>
            <month>Jun</month>
            <day>14</day>
            <volume>62</volume>
            <issue>RR-04</issue>
            <fpage>1</fpage>
            <page-range>1-34</page-range>
            <pub-id pub-id-type="pmid">23760231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strikas</surname>
                <given-names>RA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
              <collab>Advisory Committee on Immunization Practices (ACIP)</collab>
              <collab>ACIP Child/Adolescent Immunization Work Group</collab>
            </person-group>
            <article-title>Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years--United States, 2015.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Feb</month>
            <day>06</day>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>93</fpage>
            <page-range>93-4</page-range>
            <pub-id pub-id-type="pmid">25654610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <chapter-title>Measles-Mumps-Rubella Vaccine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>4</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30000093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Psarris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sindos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daskalakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chondrogianni</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Panayiotou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antsaklis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loutradis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Immunizations during pregnancy: How, when and why.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>240</volume>
            <fpage>29</fpage>
            <page-range>29-35</page-range>
            <pub-id pub-id-type="pmid">31226574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krow-Lucal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shepersky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bahta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Loehr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dooling</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <day>18</day>
            <volume>71</volume>
            <issue>46</issue>
            <fpage>1465</fpage>
            <page-range>1465-1470</page-range>
            <pub-id pub-id-type="pmid">36395065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>MMR-162 Study Group</collab>
            <article-title>Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>2921</fpage>
            <page-range>2921-2931</page-range>
            <pub-id pub-id-type="pmid">30118386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Elyazeed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Severance</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Noss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caplanusi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Povey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7&#x000a0;years of age or older: A phase III, randomized study.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>2624</fpage>
            <page-range>2624-2631</page-range>
            <pub-id pub-id-type="pmid">29902133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danziger-Isakov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <collab>AST ID Community of Practice</collab>
            </person-group>
            <article-title>Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.</article-title>
            <source>Clin Transplant</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>e13563</fpage>
            <pub-id pub-id-type="pmid">31002409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niederer-Loher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Vaccinations in pregnancy &#x02013; Don&#x02019;t miss the opportunity!].</article-title>
            <source>Ther Umsch</source>
            <year>2016</year>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>269</fpage>
            <page-range>269-73</page-range>
            <pub-id pub-id-type="pmid">27268451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>France</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Glanz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hambidge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Marcy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mullooly</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belongia</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hohman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <collab>Vaccine Safety Datalink Team</collab>
            </person-group>
            <article-title>Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.</article-title>
            <source>Pediatrics</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>e687</fpage>
            <page-range>e687-92</page-range>
            <pub-id pub-id-type="pmid">18310189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aldecoa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Archilla</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Herrero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gaig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marcos</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Measles inclusion body encephalitis.</article-title>
            <source>Clin Neuropathol</source>
            <year>2020</year>
            <season>Jul/Aug</season>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>148</fpage>
            <page-range>148-151</page-range>
            <pub-id pub-id-type="pmid">32507126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habib</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Povey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casabona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abu-Elyazeed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical trials show similar safety outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR) vaccines.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2023</year>
            <month>Dec</month>
            <day>31</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>2188852</fpage>
            <pub-id pub-id-type="pmid">36988468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Sergi</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Measles: a disease often forgotten but not gone.</article-title>
            <source>Hong Kong Med J</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-520</page-range>
            <pub-id pub-id-type="pmid">30245481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Risk of febrile seizure after measles-mumps-rubella-varicella vaccine: A systematic review and meta-analysis.</article-title>
            <source>Vaccine</source>
            <year>2015</year>
            <month>Jul</month>
            <day>17</day>
            <volume>33</volume>
            <issue>31</issue>
            <fpage>3636</fpage>
            <page-range>3636-49</page-range>
            <pub-id pub-id-type="pmid">26073015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mehlich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brockow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Darsow</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Biedermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eberlein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Gelatin-Containing Vaccines for Varicella, Zoster, Measles, Mumps, and Rubella Induce Basophil Activation in Patients with Alpha-Gal Syndrome.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2021</year>
            <volume>182</volume>
            <issue>8</issue>
            <fpage>716</fpage>
            <page-range>716-722</page-range>
            <pub-id pub-id-type="pmid">33735861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Pietrantonj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rivetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marchione</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Debalini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Demicheli</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Vaccines for measles, mumps, rubella, and varicella in children.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Apr</month>
            <day>20</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD004407</fpage>
            <pub-id pub-id-type="pmid">32309885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moro</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Arana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marquez</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barash</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hibbs</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007-2017.</article-title>
            <source>Vaccine</source>
            <year>2019</year>
            <month>Jun</month>
            <day>19</day>
            <volume>37</volume>
            <issue>28</issue>
            <fpage>3730</fpage>
            <page-range>3730-3734</page-range>
            <pub-id pub-id-type="pmid">31155414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanyaolu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okorie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marinkovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ayodele</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abbasi</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gosse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Younis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mangat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Measles Outbreak in Unvaccinated and Partially Vaccinated Children and Adults in the United States and Canada (2018-2019): A Narrative Review of Cases.</article-title>
            <source>Inquiry</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>56</volume>
            <fpage>46958019894098</fpage>
            <pub-id pub-id-type="pmid">31823676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Trondsen Pawlowski</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vaccine Adverse Events: Separating Myth from Reality.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>95</volume>
            <issue>12</issue>
            <fpage>786</fpage>
            <page-range>786-794</page-range>
            <pub-id pub-id-type="pmid">28671426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Winiecki</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beeler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>e253</fpage>
            <page-range>e253-7</page-range>
            <pub-id pub-id-type="pmid">27167117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rutter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>No effect of MMR withdrawal on the incidence of autism: a total population study.</article-title>
            <source>J Child Psychol Psychiatry</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>572</fpage>
            <page-range>572-9</page-range>
            <pub-id pub-id-type="pmid">15877763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25212.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stecula</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Quantifying the effect of Wakefield et al. (1998) on skepticism about MMR vaccine safety in the U.S.</article-title>
            <source>PLoS One</source>
            <year>2021</year>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>e0256395</fpage>
            <pub-id pub-id-type="pmid">34411172</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
